Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upOlivier Michielin, Ulrich Keilholz, Alexander C. J. van Akkooi et al.|Annals of Oncology|2019Cited by 621
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Christian U. Blank et al.|The Lancet Oncology|2021Cited by 389
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022Claus Garbe, Paul Lorigan, Bohdan Lytvynenko et al.|European Journal of Cancer|2022Cited by 320
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022Claus Garbe, Paul Lorigan, Teresa Amaral et al.|European Journal of Cancer|2022Cited by 287
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines CommitteeUlrich Keilholz, Olivier Michielin, P.A. Ascierto et al.|Annals of Oncology|2020Cited by 232